9 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 13 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 9, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow Metastases: new trials by email Literature Review of Metastases trials Research Report on Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors NCP-CD47 siRNA intratumorally injection - Solid Tumor Cancer, Metastases | Phase 1 | Not yet recruiting | West China Hospital | 9 | 2026-05-30 | 2026-05-13 |
| Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases Yttrium-90 (Y-90) resin microspheres - Metastases | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 50 | 2022-11-16 | 2026-05-26 |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab - Malignant Pleural Disease, Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 113 | 2015-05-01 | 2026-07-22 |
| Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. CELYVIR - Children, Solid Tumors | Phase 1 / Phase 2 | Completed | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | 20 | 2013-01-01 | 2016-02-19 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Amgen | 65 | 2009-03-09 | 2022-11-08 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan - Cancer, Carcinoma | Phase 1 | Completed | Amgen | 103 | 2009-01-01 | 2015-09-29 |
| Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton Radium-223 chloride (BAY88-8223) - Prostate Cancer, Metastases | Phase 1 | Completed | Bayer | 10 | 2008-08-01 | 2014-06-25 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors BMS-754807 - Neoplasms, Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 63 | 2008-04-01 | 2013-08-14 |
| Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases Ad.hIFN-β (BG00001, IDEC-201) - Colorectal Carcinoma, Metastases | Phase 1 / Phase 2 | Completed | Biogen | 44 | 2005-05-01 | 2009-07-14 |
| Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma Unconjugated IDEC-159, 111In-IDEC-159, 90Y-IDEC-159 - Colorectal Cancer, Metastases | Phase 1 / Phase 2 | Terminated | Biogen | 30 | 2005-01-01 | 2010-08-27 |
| Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer Recombinant Human Interleukin-21 - Melanoma, Kidney Neoplasms | Phase 1 | Completed | ZymoGenetics | 43 | 2004-05-01 | 2009-03-09 |
| BMS-599626 in Patients With Advanced Solid Malignancies panHer - Cancer, Metastases | Phase 1 | Completed | Bristol-Myers Squibb | 60 | 2004-03-01 | 2010-03-02 |
| ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer ALIMTA, folic acid, multi-vitamins - Metastases, Cancer | Phase 1 | Completed | Eli Lilly and Company | 2006-07-19 |
Neoplasm Metastasis (13) · Neoplasms (5) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Mesothelioma (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
Neoplastic Processes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Neoplasms (8) · Neoplasms by Site (8) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Breast Diseases (2) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
trebananib (2) · (4-((1-(3-fluorophenyl)methyl)-1H-indazol-5-ylamino)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)carbamic acid 3-morpholinylmethyl ester (1) · BMS 754807 (1) · Capecitabine (1) · Cyclophosphamide (1) · Folic Acid (1) · Lapatinib (1) · Paclitaxel (1) · Pemetrexed (1) · Topotecan (1) · Trastuzumab (1) · Yttrium-90 (1) · liposomal doxorubicin (1) · pembrolizumab (1) · radium Ra 223 dichloride (1)
Amgen (2) · Biogen (2) · Bristol-Myers Squibb (2) · Bayer (1) · Eli Lilly and Company (1) · Hospital Infantil Universitario Niño Jesús, Madrid, Spain (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · West China Hospital (1) · ZymoGenetics (1)
United States (10) · Australia (2) · Belgium (2) · France (1) · Spain (1)
Andres Forero, M.D. (1) · Ching-Wei Tzeng, MD (1) · Diana Hausman, MD (1) · Michael J. Morris, MD (1) · Roisin O'Cearbhaill, MD (1)
PMID 23653243, PMID 32053771, PMID 33737338, PMID 35045358, PMID 38321811